Techcyte, an Orem, Utah–based provider of AI-powered digital diagnostics for anatomic and clinical pathology, has secured $15 million in funding.
Investors
The round was led by Van Tuyl Companies, with participation from Zoetis Inc. and Mayo Clinic.
Van Tuyl Companies is a private family office and investment firm that manages the business interests and capital of the Van Tuyl family. The enterprise operates across multiple sectors, including real estate development, public and private securities, and venture capital. The firm actively invests in technology and growth-stage companies.
Techcyte Use of Funds
The company will use the funding to scale the Fusion platform, enhance AI capabilities using large pathology datasets, and support the company’s path to profitability.
About Techcyte
Techcyte is a healthcare technology company specializing in AI-powered digital diagnostics for anatomic and clinical pathology. Its flagship Fusion platform integrates artificial intelligence with digitized laboratory workflows to improve diagnostic accuracy, streamline case review, and enable remote pathology operations. Techcyte’s mission is to positively impact the health of humans, animals, and the environment. Headquartered in Orem, Utah, the company serves veterinary, environmental, and human health segments.
Funding Details
Company: Techcyte, Inc.
Raised: $15.0M
Round: Unknown
Funding Date: April 2026
Lead Investor: Van Tuyl Companies
Additional Investors: Zoetis Inc., Mayo Clinic
Company Website: https://techcyte.com/
Software Category: Healthcare AI / Digital Pathology
Source: https://www.businesswire.com/news/home/20260430772177/en/